Clinical update on the use of prazosin for night-time symptoms of PTSD

Abstract

Objective

To provide a clinical update on the treatment of night-time symptoms of posttraumatic stress disorder (PTSD) with prazosin, which is a centrally acting alpha-1 adrenergic receptor antagonist.

Methods

We performed a narrative review of the relevant literature and Clinical Practice Guidelines pertaining to treatment of trauma-related nightmares and insomnia with prazosin.

Results

There is a high degree of heterogeneity among the limited clinical trials to date. However, the most recent systematic review and meta-analysis supports the use of prazosin for suitable patients with PTSD-related nightmares and insomnia. Prazosin is generally well tolerated but patients may experience first-dose hypotension, orthostatic hypotension, or syncope among other side effects.

Conclusion

Although the evidence is very mixed, prazosin may be considered for a targeted time-limited trial in patients whose PTSD is dominated by nightmares and insomnia, who are unresponsive to first-line treatment with trauma-focused psychotherapy and/or evidence-based pharmacotherapies such as antidepressants, and after excluding treatable conditions like obstructive sleep apnoea. The trial should ensure that an adequate dose is used for an adequate duration (if tolerated) with monitoring of blood pressure and any emergent side effects as well as sleep-targeted benefits.

“The night is the hardest time to be alive and 4am knows all my secrets.”

― William J. Martin (formerly quoted as Poppy Z. Brite)

Posttraumatic stress disorder (PTSD) is a distressing and disabling psychiatric condition which is associated with substantial functional impairment, psychiatric and drug and alcohol comorbidities, and increased mortality risk.^1–3 The estimated lifetime prevalence of PTSD in the general population of Australia is 11% (14% for women; 8% for men), based on the National Study of Mental Health and Wellbeing 2020–2022. ⁴

Sleep disturbance represents one of the most pervasive and treatment-resistant symptom clusters in PTSD, with approximately 50–70% of affected individuals experiencing comorbid sleep disorders such as obstructive sleep apnoea (OSA), periodic limb movement disorder, or rapid eye movement sleep behaviour disorder.^3,5 Night-time symptoms, particularly trauma-related nightmares and insomnia, but also distressed awakenings, nocturnal panic attacks, and night terrors, are among the most characteristic and distressing features of PTSD. Recurrent nightmares occur in up to 70% of patients and have been linked to poorer sleep quality, elevated depression rates, and heightened suicide risk.^3,6 Insomnia (especially initial- and mid-insomnia) is also highly prevalent, affecting up to 90% of individuals with PTSD, and contributes to reduced daytime functioning and increased physical health burden, including poor cardiovascular health, reduced immune function, pain and fatigue.^3,5 Importantly, addressing comorbid sleep disorders such as OSA may improve both insomnia and daytime PTSD symptoms. ⁷

For many patients, these night-time symptoms persist despite adequate treatment of global PTSD symptomatology, indicating the need for targeted interventions. Psychological approaches such as cognitive behavioural therapy (CBT), progressive muscle relaxation, hypnosis, and eye movement desensitisation and reprocessing (EMDR) can improve sleep-related symptoms.^8,9 Specific CBT-based strategies include sleep dynamic therapy, lucid dreaming therapy, systematic desensitisation, exposure-relaxation-rescripting, and image rehearsal therapy (IRT) – the latter receiving a level-A recommendation from the American Academy of Sleep Medicine (AASM) for the treatment of PTSD-related nightmares. ⁸

Given the centrality, severity, and persistence of nightmares and insomnia in many individuals with PTSD, there is a strong clinical rationale for evaluating pharmacological agents that directly target these night-time symptoms. Prazosin has emerged as one such option and is the focus of this clinical update.

Summary of the evidence for prazosin as a treatment for PTSD night-time symptoms

Prazosin has been used for night-time symptoms of PTSD for over two decades, either as a first-line treatment or when other treatments have failed.^10–12 It is a centrally acting alpha 1-adrenergic receptor antagonist that counteracts noradrenergic stimulation, thereby potentially reducing the startle response and primitive fear response. ¹¹ This medication was originally introduced in the 1970s for the treatment of hypertension and urinary outflow obstruction caused by benign prostatic hypertrophy.

Prazosin was subsequently proposed as a treatment for hypothesized adrenergic hyperstimulation underlying PTSD-related insomnia and nightmares. Initially (2003–2014), randomized controlled trials (RCTs) demonstrated large effect sizes for improvement in PTSD-related nightmares and insomnia, prompting clinical use. A meta-analysis of the six RCTs evaluating the efficacy of prazosin in treating PTSD-related night-time symptoms was published by Kharchatryan et al. in 2016. ¹⁰ This revealed medium-to-large effect sizes. However, the sample sizes of these RCTs were relatively small (20 – 100) and the populations studied were predominantly male veterans, with only two RCTs including civilians. In contrast, the largest RCT to date by Raskind et al. in 2018 revealed negative findings with no statistically significant difference between prazosin and placebo in the relief of PTSD-related distressing dreams or improvement in sleep quality. ¹³ The sample, which comprised predominantly male veterans, was much larger (n = 304) than any of the previous RCTs, and in fact was greater than the total numbers of subjects in all of the earlier RCTs combined. Following the 2018 Raskind et al. study, AASM downgraded its recommendation for the use of prazosin for PTSD night-time symptoms in a position paper. ⁹

Zhang et al. performed a systematic review and meta-analysis of the efficacy of prazosin for PTSD night-time symptoms evaluating all RCTs to date in 2020. ¹¹ The authors demonstrated a statistically significant improvement in nightmares (standardized mean difference [SMD] = −1.13, 95%; 95% CI = −1.91 to −0.36), but there was no statistically significant difference between prazosin and placebo for sleep quality and overall PTSD symptoms. Regarding overall acceptability, there was no significant difference between the prazosin and placebo groups with respect to discontinuation for all causes (odds ratio = 1.00, 95% CI = 0.62-1.62).

The evidence for the use of prazosin for PTSD-related night-time symptoms and the generalisability of the research findings for clinical practice is limited due to significant heterogeneity between studies in terms of study populations and study size. This heterogeneity has prompted closer examination of factors that may moderate treatment response and help identify subgroups most likely to benefit. Some putative predictor variables which have been considered to possibly have a bearing on prazosin efficacy include: gender; civilian versus combat veteran status; prazosin dose; duration of treatment with prazosin; concurrent medication; and current use of alcohol. ¹² Mendes et al. conducted a systematic review and meta-regression analysis (10 RCTs comprising 648 patients) to address this question in 2025. ¹² They found that prazosin significantly improved insomnia (SMD = − 0.654, p = .043) and nightmares (SMD = − 0.641, p = .025), but not overall PTSD symptoms (SMD = − 0.428, p = .077). The meta-regression analysis showed that none of the putative variables were predictors of prazosin efficacy except concurrent medication. Higher benzodiazepine coadministration was associated with greater improvement in insomnia (β = − 0.046; p = .01). The authors considered exploring whether baseline standing blood pressure (as a possible biomarker of a hyperadrenergic state) is a predictor of prazosin efficacy as part of their meta-regression analysis. However, there were no significant differences in baseline blood pressure readings in the four RCTs which provided these data in both the prazosin and placebo groups, and therefore this analysis was not possible to be carried out.

The mixed research findings help explain why enthusiasm for prazosin has become more circumscribed and why guideline recommendations have evolved with greater caution. Although there is broad consensus among current Clinical Practice Guidelines (CPGs) on the primacy of trauma-focused psychotherapy interventions for the treatment of PTSD, there are some differences in emphasis in their recommendations regarding the clinical indications for prazosin for night-time PTSD symptoms (Table 1), reflecting uncertainties exposed by the mixed evidence base described above.^9,14–20

Table 1.

Clinical practice guidelines: Indications for treatment of PTSD night-time symptoms with prazosin

Guideline(Year)	Recommendation for prazosin	First-line treatments	Comments
NICE Guidelines 2018 (reviewed April 2025) 18	• No formal recommendation for prazosin for PTSD-related nightmares or insomnia (use remains an off-label, case-by-case specialist decision rather than guideline-endorsed treatment)	• Trauma-focused psychological therapies	• There is no evidence that prazosin is effective for global PTSD symptoms as a monotherapy, and evidence for benefit on overall sleep quality is conflicting
		• If patient prefers medication, consider an SSRI (e.g. sertraline) or venlafaxine
NHS (updated 2025) 20	• May be used for patients with PTSD-related nightmares associated with distress/functional impairment as monotherapy or as an adjuvant to other medications used for global PTSD symptoms as a specific addition to reduce nightmares.	• Psychological therapies	• There is no evidence that prazosin is effective as monotherapy for global PTSD symptoms and there is conflicting evidence for its efficacy on overall sleep quality
	• Patients should be made aware that this is not a licensed indication for prazosin	• SSRIs, SNRIs for global symptoms	• Cautions about added antihypertensive affect when medications such as phosphodiesterase type 5 inhibitors and other antihypertensives are being used
The Maudsley Prescribing Guidelines in Psychiatry (2025) 17	• Recommended as a second-line treatment for patients with PTSD experiencing ‘nightmares and sleep disturbances’	• First-line pharmacotherapy recommendations are paroxetine, sertraline, fluoxetine and venlafaxine	• Prazosin targeted specifically for night-time symptoms
APA (2025) 14	• Insufficient evidence to recommend for or against the use of prazosin	• Trauma-focused cognitive behavioural therapy, cognitive processing therapy, and prolonged exposure	• Second line treatments include cognitive therapy, EMDR, narrative exposure therapy (NET), fluoxetine, paroxetine, sertraline and venlafaxine
VA/DoD Clinical Practice Guideline (CPG) for posttraumatic stress disorder (PTSD) and acute stress disorder (ASD) 19	• Earlier versions (e.g. 2010 VA/DoD guideline) recommended prazosin for nightmares and sleep disturbances with level B recommendation (fair evidence that benefits outweigh harms)	• Paroxetine, sertraline and venlafaxine are the recommended pharmacotherapy for ‘overall’ PTSD symptoms	• There is a suggestion against the use of prazosin for overall PTSD symptoms
	• More recently, after larger trials (notably Raskind et al. 2016) failed to show prazosin outperforming placebo, newer guidance (VA/DoD 2023) became more cautious, with the ‘suggestion’ (but not ‘recommendation’) of prazosin for PTSD-related nightmares but with the caveat that the ‘quality is evidence is low’
American Academy of Sleep Medicine (AASM) 2018 9	• Suggest prazosin may be used for PTSD-associated nightmares (optional use)	• Image rehearsal therapy (IRT) is the only treatment explicitly recommended for PTSD-related nightmares	• Prazosin not recommended for insomnia per se; AASM’s insomnia guidelines suggest CBT-I and approved hypnotics
Australian guidelines for the prevention and treatment of acute stress disorder, posttraumatic stress disorder, and complex PTSD (2020) 15	• Prazosin is mentioned among adjunctive/‘other drugs’ for nightmare/sleep disturbance symptoms in patients with PTSD but not as a first-line or strongly recommended primary treatment	• Psychological therapies emphasized as a first preference	• Developed and published by Phoenix Australia and supported by RANZCP and RACGP
2025 Therapeutic Guidelines (Australia) 16	• Recommended for PTSD-associated nightmares and sleep disturbance	• Fluoxetine, fluvoxamine, citalopram, escitalopram, paroxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine recommended for global PTSD symptoms	• Highlights that ‘evidence is conflicting’ regarding use of prazosin for night-time PTSD symptoms

NICE/NHS: National Institute for Health and Care Excellence/National Health Service.

APA: American Psychological Association.

VA/DoD: Department of Veterans Affairs (VA)/Department of Defence.

RANZCP: Royal Australian and New Zealand College of Psychiatrists.

RACGP: Royal Australian College of General Practitioners.

CBT-I: Cognitive Behavioural Therapy for Insomnia.

IRT: Image Rehearsal Therapy.

EMDR: Eye Movement Desensitisation and Reprocessing.

Despite this variability in guideline recommendations, prescribing practices in real-world clinical settings appear more consistent. A relatively recent survey of Australian and New Zealand psychiatrists showed that the most frequently used guideline for PTSD management was over 10 years old and used by less than half (48%) of respondents. ²¹ Peer-reviewed scientific journals were the most common additional source used by psychiatrists to inform their clinical practice. For the targeted treatment of PTSD-related nightmares 86% of psychiatrists reported having prescribed prazosin, with only 2% indicating that they found it ineffective in decreasing nightmare frequency and/or intensity, despite negative findings in a large RCT.

These issues highlight the need for pragmatic, evidence-informed guidance to support clinicians in their judicious use of prazosin. We propose practical suggestions (Table 2) for treatment of night-time PTSD with prazosin based on the above summary of research to date and a synthesis of the CPGs, from Table 1.^9,14–20

Table 2.

Practical suggestions regarding treatment of night-time PTSD symptoms with prazosin

Who to treat11,12,14,16–20	Consider prazosin when nightmares and/or insomnia are prominent, distressing, and cause functional impairment, especially if:
	• Nightmares persist despite trauma-focused psychotherapy and/or SSRI/SNRI treatment
	• Failed trial of sleep hygiene and exclusion of co-occurring sleep disorder, for example, OSA
	Consider alternative treatment to prazosin when:
	• Primary complaint is daytime PTSD symptoms without significant sleep disturbance
	• Baseline orthostatic hypotension, syncope history, or patient is taking polypharmacy hypertension treatments
	Patients should be informed that the evidence for prazosin in PTSD is very mixed
	Shared-decision making between patient and clinician following discussion of the risk benefit profile
Dosing and titration 11,16,18,20	Start at a low dose at bedtime (to limit first-dose hypotension)
	• Typical starting dose: 0.5–1 mg nocte (elderly/frail: consider 0.5 mg nocte)
	• Increase to 2 mg nocte after 2 nights
	• Assess response after 1 week to determine whether further dose increments are required
	• If so titrate by 1–2 mg every week based on improvements in insomnia and nightmare frequency/intensity and if orthostatic hypotension or other side effects develop
	• Typical effective dose range is 3–15 mg nocte; some patients, especially veterans, may require doses >15 mg nocte
	• If no benefit at 15 mg nocte, re-evaluate diagnosis/targets (consider possible parasomnias, OSA, REM-BD)
	• ‘Correct’ dose = lowest dose that provides the optimal response i.e. use the lowest effective dose
Safety and monitoring12,16,18,20	• Check blood pressure/heart rate at baseline and after each upward titration in dose; warn about first-dose syncope, especially within 2-4 hours of initiation or dose increases (caution regarding driving or using heavy machinery)
	• Be aware of common side effects: dizziness, light-headedness, fatigue, dry mouth, nasal congestion -these are usually dose-related and often transient; priapism is a rare side effect; limited long-term follow-up studies but no evidence of late-onset side effects in patients with treated with prazosin for PTSD
	• Be aware of potential drug interactions: increased risk of hypotension if used with other antihypertensives; avoid additional α1-blockers (e.g. tamsulosin) unless urologically required and BP allows
	• Existing benzodiazepine treatment: adding prazosin may possibly permit (careful) reduction in benzodiazepine dose
	• Comorbidities: screen for parasomnia such as OSA, substance or alcohol use, caffeine use
	• Pregnancy/lactation: no teratogenic effects in animal studies but safety in human pregnancy not certain; prazosin is excreted in breast milk, but data on safety in breastfeeding are limited; consider risk benefit profile; consult perinatal services if required
Assessment of Response9,11,12,16,20	• Monitor target symptoms (nightmares/insomnia) for possible improvement
	• Consider using instruments such as dreams and Nightmares Severity Index, Insomnia Severity Index, and sleep diaries or actigraphy when feasible
	• Assess for functional gains (e.g. less daytime fatigue and less absenteeism)
	• There are no evidence-based recommendations for how long prazosin should be used for in the treatment of PTSD
	• Efficacy and tolerability to be regularly reviewed, and when there is clear clinical evidence for ongoing benefit it can be continued
What to do if no response9,10,12,17,20	• Check dose (non-response may occur at 1–2 mg nocte) and ensure adequate treatment duration; a minimum trial period of 4–8 weeks at a well-tolerated or maximally tolerated target dose is recommended before deciding non-response a
	• Check adherence, caffeine/alcohol/substance use, and medications that worsen nightmares (e.g. some SSRIs and SNRIs in early titration)
	• Consider switching to image rehearsal therapy or other psychological strategy (if not already tried)

OSA = Obstructive Sleep Apnoea.

REM-BD = Rapid Eye Movement Sleep Behaviour Disorder.

SSRI = Selective Serotonin Reuptake Inhibitor.

SNRI = Serotonin and Noradrenaline Reuptake Inhibitor.

^aSome studies have found responses within 1–3 weeks of reaching the target dose, but others have demonstrated no response until between 4 and 8 weeks. ¹⁰ The Mendes et al. ¹² meta-regression analysis found no association between either prazosin dose or prazosin duration, and efficacy – the authors of that paper suggested that this might imply that prazosin’s therapeutic effects are achieved relatively rapidly indicating a possible ceiling effect.

Given that important gaps in the evidence base remain, there is a need for further methodologically robust research into the use of prazosin for PTSD night-time symptoms, including prospective clinical trials with large sample sizes examining specific population groups and predictors of efficacy. Further comprehensive research into the aetiopathogenesis and treatment of insomnia and sleep disorders in PTSD, including nightmares, is needed to address these troubling and debilitating symptoms.

A limitation of this paper is that a narrative review was employed rather than a systematic review. However, the narrative approach allowed for a clinically focused synthesis of key trials, meta-analyses (including a 2025 meta-analysis), and clinical guideline recommendations relevant to everyday practice.

Conclusion

The cornerstone of PTSD treatment remains trauma-focused psychotherapy and evidence-based pharmacotherapy, especially antidepressants. In clinical practice, individuals with PTSD may opt for psychotherapy, pharmacotherapy, or a combination of both, while some may choose to decline these options altogether. In this context, it is valuable to be able to offer a range of treatment approaches tailored to individual needs and preferences. For instance, a person experiencing distressing nightmares may choose symptomatic treatments such as image rehearsal therapy, or prazosin, or both.

Although the evidence is very mixed, given that a very recent meta-analysis demonstrated a medium to large treatment effect size for nightmares and insomnia, prazosin may be considered for a targeted time-limited trial in patients with significant nightmares and insomnia arising from PTSD. Such a trial involves the use of an adequate dose for an adequate duration with monitoring of blood pressure and sleep-targeted benefits (see Table 2). If effective, prazosin may be continued as an ongoing treatment; however, there are currently no evidence-based guidelines specifying the optimal duration of therapy for PTSD.

Based on the most recent evidence for people with PTSD, prazosin may relieve insomnia and nightmares. As more research uncovers further evidence, perhaps newer and more effectively targeted treatments will become available.